Business

Novartis Seeks U.S. Approval for Two Smoker’s Cough Drugs

The Aug. 12, 2005 file photo shows the logo of Swiss company Novartis in Basel, Switzerland. Swiss pharmaceutical giant Novartis AG announced a series of multibillion-dollar deals Tuesday, April 22, 2014 with other major pharmaceutical companies that it said would reduce sales but boost profitability, while affecting some 15,000 of its employees globally. (AP Photo/Keystone, Steffen Schmidt)
The Aug. 12, 2005 file photo shows the logo of Swiss company Novartis in Basel, Switzerland. AP Photo/Keystone, Steffen Schmidt)

 

(Bloomberg) – Novartis AG applied for U.S. regulatory approval for two drugs to treat smoker’s cough that analysts estimate could generate an additional $1.4 billion in annual sales for the Swiss drugmaker.

Third-phase clinical tests for QVA149 and NVA237 showed “positive” results for the treatment of chronic obstructive pulmonary disorder, or smoker’s cough, Basel-based Novartis said today in a statement. The filing was made in the fourth quarter of last year, the company said.

Drugmakers are introducing new respiratory treatments as existing drugs such as GlaxoSmithKline Plc’s Advair lose intellectual property rights. COPD kills a person every 10 seconds and will become the third-highest cause of death worldwide by 2030, according to the World Health Organization. The disease is characterized by breathlessness, excess saliva, mucus in the airways and a chronic cough.

Novartis’s decision to apply for approval of both products as twice-daily treatments may put them at a disadvantage to once-daily therapies such as GlaxoSmithKline’s Anoro and Boehringer Ingelheim GmbH’s Spiriva, analysts from Barclays Plc wrote in a note today.

READ MORE

Tags
Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *


By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, http://www.washingtoninformer.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Back to top button

My News Matters to me - Washington Informer Donations

Be a Part of The Washington Informer Legacy

A donation of your choice empowers our journalists to continue the work to better inform, educate and empower you through technology and resources that you use.

Click Here Today to Support Black Press and be a part of the Legacy!

Subscribe today for free and be the first to have news and information delivered directly to your inbox.


By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, http://www.washingtoninformer.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
Close

Adblock Detected

Please consider supporting us by disabling your ad blocker